Skip to content
  • Saturday, 15 August 2026
  • 1:08 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • AviadoBio Expands Exclusive Licensing of vMiX Gene-Silencing Platform to Encompass All Human Therapeutic Areas
Pharmaceutical R&D

AviadoBio Expands Exclusive Licensing of vMiX Gene-Silencing Platform to Encompass All Human Therapeutic Areas

Teuku Ryan Jun 17, 2026 0

AviadoBio has significantly broadened its strategic horizons through an expanded exclusive licensing agreement with King’s College London. This pivotal development…

Read More
Exploding Primordial Black Holes and Dark Charge May Solve the Mystery of Ultra-High-Energy Neutrinos and Dark MatterCVC Capital Partners and Groupe Bruxelles Lambert Launch $12.4 Billion Takeover Bid for Recordati, Signaling Potential Shift to Private OwnershipBioengineered Bone Marrow-on-a-Chip Platform Revolutionizes Human Hematopoiesis Research and Drug Toxicity ScreeningPaternal Age and the Evolutionary Advantage of Harmful Sperm Mutations: A Comprehensive Analysis of Genetic Risks to Future Generations
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ